Latest Healthcare News

Resmed Inc. reported a robust 10% revenue increase and a 19% rise in operating profit for fiscal 2025, alongside a 13% dividend hike, driven by strong demand for sleep and breathing health devices and growth in digital health software.

Syntara Limited reported a $3.7 million cash outflow from operations in the June quarter but bolstered its balance sheet with an $18.5 million capital raise, ending the period with $15.1 million in cash.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global growth ambitions, while targeting an additional USD 6 million from strategic investors and unlocking AUD 3 million in R&D grants.

Advanced Health Intelligence Ltd has locked in up to AUD 5.5 million from Oakley Capital Partners, reinforcing its capital base as it pushes toward reinstatement on the ASX and broader growth ambitions.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.